Using nanotechnology to improve immune treatment for lymphoma
Local nano-immune modulation for the systemic treatment of lymphoma
['FUNDING_CAREER'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10884825
This study is testing a new treatment that uses tiny gold particles and light to help your immune system fight back against tough-to-treat B cell lymphomas, and it’s looking for patients to see how well it works compared to standard therapies.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10884825 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapy that combines immune-based nanotechnology with photothermal therapy to enhance treatment for relapsed or refractory B cell lymphomas. The approach aims to modify both local and systemic immune environments to improve the effectiveness of existing immunotherapies, which often struggle due to suppressive tumor conditions. By utilizing specially designed gold nanoparticles activated by near-infrared light, the therapy seeks to generate a robust T-cell response against lymphoma cells. Patients may be involved in evaluating how well this new treatment works compared to traditional methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory B cell lymphomas who have not responded well to standard therapies.
Not a fit: Patients with early-stage lymphoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with difficult-to-treat lymphomas, potentially improving survival rates and quality of life.
How similar studies have performed: While the use of photothermal therapy in solid tumors has shown promise, this specific application in lymphoma is novel and has not been extensively tested.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIN, ADAM YUH — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: LIN, ADAM YUH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.